Uncategorized

January Issue

This morning Merck (NYSE:MRK) fourth quarter and full years results for 2006. Januvia, the company’s new treatment for type 2 diabetes achieved sales of $42 million in the fourth quarter. Everyone is watching Januvia sales and it’s potential impact on Byetta from Amylin (NASDAQ:AMLN) who reports their earnings today after the market closes. After getting off to a strong start, Januvia prescriptions have slowed over the past few weeks while...

Abbott Reports

This morning Abbott (NYSE:ABT) reported fourth quarter and full year 2006 results. Looking at the diabetes care division Diabetic Investor’s previous reports that growth was slowing turned out to be highly accurate. In the fourth quarter Abbott Diabetes Care sales declined by 2.1% domestically compared to same quarter in 2005, worldwide sales in the quarter grew an anemic 1.5%. For the full year the results weren’t much better with sales...

JNJ Reports, Pfizer “Full Court Press” on Exubera

This morning Johnson and Johnson (NYSE:JNJ) reported fourth quarter and full year 2006 results. For the full year the LifeScan unit reported worldwide sales of slightly above $2 billion a 9% increase over 2005, in the fourth quarter sales reached $542 million a 12% over the comparable quarter in 2005. While everyone associates JNJ’s primary diabetes focus with their LifeScan unit, the company also has several type 2 drugs...

Medtronic Update

This morning Medtronic (NYSE:MDT) stated that they should have a semi-closed loop insulin pump system ready mid to late 2008. The company also stated they have completed enrolment for their STAR 3 trial which will compare insulin pump therapy to multiple daily injection therapy. More importantly the company reiterated their already stated position that they will vigorously defend their extensive patent portfolio. While it goes largely unnoticed in the...

Abbott – GE and what it says about the future of the BGM market

The big news today is the rumored deal between Abbott (NYSE:ABT) and GE (NYSE:GE). According to a variety of reports GE would purchase Abbott’s diagnostics division for $5 billion. These same reports state that this reported sale does not include Abbott’s diabetes business. The Chicago Tribune, Abbott’s home town paper, stated the diabetes business was among Abbott’s fastest growing business segments. Diabetic Investor thinks the Tribune should stick to covering...

Dexcom – More Problems

Yesterday at the JP Morgan conference Dexcom (NASDAQ:DXCM) announced that fourth quarter revenues would come in well below Street estimates. The company stated that revenues for the quarter would come in at $835,000, while the Street was expecting revenues of $1 to $1.2 million. Also coming in below estimates were starter kits sales which came in at 840 for the quarter below Street estimates of 1,000 to 1,200. It appears...

Diabetic Investors Hanukkah Gifts

With the holiday season upon us Diabetic Investor has some gifts for subscribers. Since we’re in the midst of the Festival of Lights it’s only appropriate that we hand out eight Hanukkah gifts. 1. 1. To shareholders of Amylin (NASDAQ:AMLN) a buyout offer from anyone but Lilly (NYSE:LLY). 2. 2. To the new management team at Abbott (NYSE:ABT) Diabetes Care a real understanding of the...

Having the edge

With the type 2/pre-diabetes market gaining momentum there are several unanswered questions: 1. Will Januvia from Merck (NYSE:MRK) change the dynamics of the market? 2. Are there hidden issues with Januvia that are being ignored? 3. Will Avandia from GlaxoSmithKline (NYSE:GSK) and Actos marketed by Lilly (NYSE:LLY) made by Takeda, survive the arrival of Januvia? 4. ...

The Expanding World of Type 2 Medications

As Diabetic Investor covered in our year end issue, the type 2 and pre-diabetes markets, are gaining the attention of pharmaceutical companies across the globe. Further evidence of this appeared yesterday when OSI Pharmaceuticals (NASDAQ:OSIP) and Bristol-Myers Squibb (NYSE:BMY) announced an agreement where OSI granted BMY a worldwide non-exclusive license under its DPP-4 patent portfolio for the development of DPP-4 inhibitors to treat type 2 diabetes. BMY already has saxagliptin,...

The Expanding World of Type 2 Medications

As Diabetic Investor covered in our year end issue, the type 2 and pre-diabetes markets, are gaining the attention of pharmaceutical companies across the globe. Further evidence of this appeared yesterday when OSI Pharmaceuticals (NASDAQ:OSIP) and Bristol-Myers Squibb (NYSE:BMY) announced an agreement where OSI granted BMY a worldwide non-exclusive license under its DPP-4 patent portfolio for the development of DPP-4 inhibitors to treat type 2 diabetes. BMY already has saxagliptin,...